Christian Beyer

Summary

Affiliation: University of Erlangen-Nuremberg
Country: Germany

Publications

  1. ncbi Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis
    Christian Beyer
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Res Ther 11:220. 2009
  2. ncbi Inhibition of glycogen synthase kinase 3? induces dermal fibrosis by activation of the canonical Wnt pathway
    Christina Bergmann
    Correspondence to Jörg H W Distler, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:2191-8. 2011
  3. ncbi Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis
    Clara Dees
    Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:1304-10. 2011
  4. ncbi Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis
    Nicole Reich
    Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:737-45. 2012
  5. ncbi Activation of canonical Wnt signalling is required for TGF-?-mediated fibrosis
    Alfiya Akhmetshina
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    Nat Commun 3:735. 2012
  6. ncbi Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis
    Angelika Horn
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:785-9. 2012
  7. ncbi Platelet-derived serotonin links vascular disease and tissue fibrosis
    Clara Dees
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    J Exp Med 208:961-72. 2011
  8. ncbi ?-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis
    Christian Beyer
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:761-7. 2012
  9. ncbi Innovative antifibrotic therapies in systemic sclerosis
    Christian Beyer
    Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Curr Opin Rheumatol 24:274-80. 2012
  10. ncbi Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts
    Nicole Reich
    Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    J Cell Mol Med 15:756-62. 2011

Collaborators

Detail Information

Publications11

  1. ncbi Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis
    Christian Beyer
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Res Ther 11:220. 2009
    ..Altogether, hypoxia might play a central role in pathogenesis of SSc by augmenting vascular disease and tissue fibrosis...
  2. ncbi Inhibition of glycogen synthase kinase 3? induces dermal fibrosis by activation of the canonical Wnt pathway
    Christina Bergmann
    Correspondence to Jörg H W Distler, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:2191-8. 2011
    ..A study was undertaken to define the role of GSK-3 in fibroblast activation and in experimental models of systemic sclerosis (SSc)...
  3. ncbi Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis
    Clara Dees
    Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:1304-10. 2011
    ..Dermal fibroblasts from patients with systemic sclerosis (SSc) release excessive amounts of collagen resulting in tissue fibrosis. The molecular mechanisms underlying this pathological activation are incompletely understood...
  4. ncbi Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis
    Nicole Reich
    Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:737-45. 2012
    ..This study analysed the antifibrotic effects of the selective c-Jun N-terminal kinase (JNK) inhibitor, CC-930, which recently entered first clinical trials as a novel antifibrotic approach...
  5. ncbi Activation of canonical Wnt signalling is required for TGF-?-mediated fibrosis
    Alfiya Akhmetshina
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    Nat Commun 3:735. 2012
    ..These findings demonstrate that canonical Wnt signalling is necessary for TGF-?-mediated fibrosis and highlight a key role for the interaction of both pathways in the pathogenesis of fibrotic diseases...
  6. ncbi Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis
    Angelika Horn
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:785-9. 2012
    ..Effective antifibrotic treatments are not available. Here, the authors investigated inhibition of hedgehog signalling by targeting Smoothened (Smo) as a novel antifibrotic approach...
  7. ncbi Platelet-derived serotonin links vascular disease and tissue fibrosis
    Clara Dees
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    J Exp Med 208:961-72. 2011
    ..These findings suggest that 5-HT/5-HT(2B) signaling links vascular damage and platelet activation to tissue remodeling and identify 5-HT(2B) as a novel therapeutic target to treat fibrotic diseases...
  8. ncbi ?-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis
    Christian Beyer
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:761-7. 2012
    ..catenin is an integral part of adherens junctions and a central component of canonical Wnt signaling. Here, the authors addressed the role of ?-catenin in fibroblasts for the development of SSc dermal fibrosis...
  9. ncbi Innovative antifibrotic therapies in systemic sclerosis
    Christian Beyer
    Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Curr Opin Rheumatol 24:274-80. 2012
    ..Nevertheless, promising antifibrotic agents are emerging from translational studies with some having already entered clinical trials...
  10. ncbi Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts
    Nicole Reich
    Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    J Cell Mol Med 15:756-62. 2011
    ..Our data suggest that MPs may contribute to the hypervascularization of inflamed joints in patients with rheumatoid arthritis...
  11. ncbi EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research
    Christian Beyer
    Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:1178-82. 2011
    ..These recommendations might also be followed by other SSc consortia to enable exchange of biosamples between different SSc initiatives and might serve as a template for biobanking initiatives in other rheumatic diseases...